Agios Pharmaceuticals Inc (STU:8AP)
€ 42 2.6 (6.6%) Market Cap: 2.40 Bil Enterprise Value: 1.91 Bil PE Ratio: 0 PB Ratio: 3.45 GF Score: 41/100

Agios Pharmaceuticals Inc Investor Event to Review AG-270 Phase 1 Data and Research Transcript

Oct 27, 2019 / 10:30PM GMT
Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Hello. How's everybody doing? Holly, Kendra, do you want me to start? I do what you guys tell me to do. So okay. How's everybody doing? Good to see you, good to see you. Thanks for being with us tonight. So we are very pleased to be here to focus on and talk about the AG-270 MAT2A inhibitor data tonight. I know it's been a long-awaited moment to dig into this data set. So hopefully, some of you had a chance to go through the presentations today. But we'll spend this evening on the topic for as long as you want to stay here with us and talk about it.

These are the forward-looking statements. I'm not going to read the whole thing, you know what they are. I just wanted to kick off the discussion with -- I have 2 slides. One is to introduce the presenters to you. Some of you, I think, have had the pleasure of interacting with Kevin Marks, our Head of Biology in the past. So Kevin is going to present the biology around the molecule and the program tonight. We then have Chris Bowden, all of you know him, our Chief Medical Officer, who

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot